Trial · NCT02850263
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Best Corrected Visual Acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters in patients with DMO treated with intravitreal aflibercept | Baseline and 12 months | BCVA (Best Corrected Visual Acuity): process to measure with the help of a retinoscope, auto-refractor or phoropter how much power is needed to bring the eye to normal, perfectly focused vision) when performed in addition to that at baseline and 12 months. ETDRS Chart: charts imprinted with lines of letters decreasing in size from largest on top to smallest on the bottom to determine visual acuity. |
| Primary | Change in central subfield thickness (CST) as determined by Spectral Domain Optical Coherence Tomography (SD-OCT) in patients with DMO treated with intravitreal aflibercept | Baseline and 12 months | |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters in patients with DMO treated with intravitreal aflibercept | Baseline and 24 months | |
| Secondary | Change in central subfield thickness (CST) as determined by Spectral Domain Optical Coherence Tomography (SD-OCT) in patients with DMO treated with intravitreal aflibercept | Baseline and 24 months | |
| Secondary | Change in non-refracted visual acuity in patients with DMO treated with intravitreal aflibercept | Baseline, 12 and 24 months | |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters in patients with DMO treated with intravitreal aflibercept differentiated by BCVA baseline characteristics | Baseline, 12 and 24 months | |
| Secondary | Change in central subfield thickness (CST) in patients with DMO treated with intravitreal aflibercept differentiated by CST baseline characteristics | Baseline, 12 and 24 months | |
| Secondary | Proportion (%) of patients discontinuing intravitreal aflibercept treatment | Baseline, 12 and 24 months | |
| Secondary | Time between the decision to treat for patients with DMO who have not received any previous anti-VEGF treatment | Baseline | |
| Secondary | The time between the date of DMO diagnosis for patients with DMO who have received any previous anti-VEGF treatment | Baseline | |
| Secondary | Proportion (%) of treated eyes with 5, 10 and 15 letter gain / loss | Baseline, 12 and 24 months | |
| Secondary | Proportion (%) of sites that adhere to their stated treatment protocol | 12 and 24 months | |
| Secondary | Change in QoL score measured by NEI VFQ-25 | Baseline, 12 and 24 months | |
| Secondary | Change in macular volume | Baseline, 12 and 24 months | |
| Secondary | Change in Best Corrected Visual Acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters | Baseline, 12 and 24 months | |
| Secondary | Change in non-refracted visual acuity (VA).for the fellow eye | Baseline, 12 and 24 months | |
| Secondary | Number of DMO treatments required for the fellow eye | Baseline, 12 and 24 months | |
| Secondary | Number of visits performed (resources) to assess the fellow eye | Baseline, 12 and 24 months | |
| Secondary | Number of clinical procedures performed (resources) to assess the fellow eye | Baseline, 12 and 24 months | |
| Secondary | Number of adverse events as a measure of safety and tolerability | 24 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02850263/registered